Corbus Pharmaceuticals (CRBP)
Develops CRB-701 for oncology and CRB-913 for obesity.
$7.80
vs last close−0.07 (−0.95%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 3.01% | 581.6K shares | |
|---|---|---|---|
| 13 holders · as of Sep 15, 2026 | |||
| Strategic holders | 24.61% | 4.76M shares | |
| 3 holders · as of Jul 27, 2026 | |||
| Other | 72.38% | 14.00M shares | |
| remainder | |||
19.34M company shares as of Sep 23, 2026 · holders as of their latest filing
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 13.36% | 2.34M | 13G | Dec 15, 2025 |
| Octagon Investments Master Fund LPincl. Octagon Capital Advisors LP, Ting Jia | 9.30% | 1.12M | 13G | Oct 11, 2024 |
| Aberdeen Group plc | 7.53% | 1.32M | 13G | Jan 16, 2026 |
| BlackRock, Inc. | 5.90% | 1.09M | 13G | Jul 27, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 14, 2026 | Yong Bendirector | Sale | 2,000 | $7.84 | 9,383 |
| Aug 11, 2026 | Nishant C. Saxenaofficer: Chief Business Officer | Purchase | 2,600 | $9.63 | 77,900 |
| Aug 7, 2026 | Sean F. Moranofficer: Chief Financial Officer | Sale | 12,000 | $10.08 | 84,694 |
| Aug 7, 2026 | Yuval Cohendirector, officer: Chief Executive Officer | Sale | 17,000 | $10.08 | 157,316 |
| Jun 10, 2026 | John Kenneth Jenkinsdirector | Sale | 4,800 | $7.91 | 3,833 |
| Jun 10, 2026 | Anne Altmeyerdirector | Sale | 2,412 | $7.91 | 7,579 |
| Jun 10, 2026 | Winston Kungdirector | Sale | 2,026 | $7.91 | 12,140 |
| Jun 2, 2026 | Nishant C. Saxenaofficer: Chief Business Officer | Purchase | 4,500 | $7.33 | 66,300 |
| Jun 3, 2026 | Nishant C. Saxenaofficer: Chief Business Officer | Purchase | 9,000 | $7.58 | 75,300 |
| Mar 2, 2026 | Dominic Smethurstofficer: Chief Medical Officer | Sale | 6,097 | $8.30 | 89,790 |
House and Senate disclosures
Not reported.